Suggested remit: To appraise the clinical and cost effectiveness of faricimab within its marketing authorisation for treating wet age-related macular degeneration.
 
Status In progress
Process STA 2018
ID number 3898

Provisional Schedule

Committee meeting: 1 01 June 2022
Expected publication 10 August 2022

Project Team

Project lead Louise Jafferally

Email enquiries

Consultees

Companies sponsors Roche (faricimab)
Others Department of Health and Social Care
  NHS England
  NHS Hammersmith and Fulham CCG
  NHS South Norfolk CCG
  Welsh Government
Patient carer groups Eyecare Trust
  Fight for Sight
  Macular Society
  National Federation of the Blind of the UK
  OBAC
  Royal National Institute of Blind People
  SeeAbility
  Sense
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Thomas Pocklington Trust
Professional groups Association of Optometrists
  British and Irish Orthoptic Society
  British Geriatrics Society
  British Ophthalmic Anaesthesia Society
  College of Optometrists
  Health Lumen
  Optical Confederation
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Ophthalmologists
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  UK Clinical Pharmacy Association
  UK Ophthalmic Pharmacy Group

Commentators

Associated guideline groups National Clinical Guideline Centre
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies Bayer (aflibercept)
  Novartis (brolucizumab, ranibizumab)
  Organon Pharma (bevacizumab)
  Pfizer (bevacizumab)
  Roche (bevacizumab)
  Thornton & Ross (bevacizumab)
  Zentiva (bevacizumab)
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Alliance
  NHS Confederation
  Scottish Medicines Consortium
  Wales Council for the Blind
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Eyes and Vision Group
  Eye Hope
  Genomics England
  Institute of Ophthalmology, University College London
  MRC Clinical Trials Unit
  National Eye Research Centre Charity
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
21 September 2021 Invitation to participate
21 September 2021 In progress. Invitation to Participate issued
20 April 2021 - 19 May 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance